Crossref

1. Types and predictors of interferon/ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus

- Ibtesam Ibrahim El-Dosouky

- Soha Abdel-Moneim El Hawari

- Mohamed Hassan Emara

- Emad Fawzi Hamed

2. Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

- Reza Karbasi-Afshar

- Amin Saburi

3. Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review

- Wenxue Zhao

- Fanpu Ji

- Shanshan Yu

- Zongfang Li

- Hong Deng

4. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct‐acting antivirals

- A. Olveira

- L. Domínguez

- J. Troya

- A. Arias

- F. Pulido

- P. Ryan

- L. M. Benítez

- J. González‐García

- M. L. Montes

5. Triple Combination with Direct Acting Antivirals in the Treatment of Hepatitis C Does not Prolong the QT Interval

- Jakub Šimka

- Radek Pudil

- Monika Fialová

- Filip Varhaník

- Stanislav Plíšek

- Petr Pařízek

6. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response

- Abdul-Quddus Mohammed

- Ranshaka Auckle

- Hai-Ling Li

- Si-Ling Xu

- Lu Liu

- Dong-Dong Zhao

- Wen-Liang Che

7. Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C−infected patients with thalassemia

- Arezoo Khosravi

- Hamidreza Karimi‐Sari

- Mahdi Abedi‐Andani

- Bita Behnava

- Ali Namvar

- Ali Anvar

- Seyed Moayed Alavian

8. Factors associated with treatment interruption for hepatitis C

- Luciana Oliveira de Rezende Melo

- Denise Leite Maia Monteiro

- Nádia Cristina Pinheiro Rodrigues